Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Research Paper: Anti-Myelin Oligodendrocyte Glycoprotein in Aquaporin-4 Negative Neuromyelitis Optica Spectrum Disorder Publisher



Shaygannejad V1, 2 ; Barzegar M1, 2 ; Manouchehri N1, 2 ; Esmaeil N1, 3 ; Nehzat N1 ; Badihian S1, 2 ; Ashtari F1, 2 ; Mirmosayyeb O1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Caspian Journal of Neurological Sciences Published:2021


Abstract

Background: The absence of Aquaporin-4 Antibody (AQP4-Ab) in a fraction of the Neuromyelitis Optica Spectrum Disorder (NMOSD) patients has led to a search for other serologic markers. Myelin Oligodendrocyte Glycoprotein (MOG) is a protein component of the myelin sheets encapsulating the neural fibers. Objectives: We aimed to compare the presence and levels of anti-MOG (Ig-G) in a group of seronegative NMOSD patients with a healthy control group. Materials & Methods: In this cross-sectional study, 30 NMOSD patients with negative AQP-Ab status, who were referred to the Neurology Clinic of Kashani University Hospital in Isfahan City, Iran, from March 2015 to March 2016, and 26 healthy controls were consecutively recruited. Their baseline demographic and clinical data were recorded. Serum anti-MOG levels were measured in both groups. The obtained data were analyzed using the Student t-test, Mann-Whitney U, and Chisquare test in SPSS V. 18. Results: The anti-MOG test results were statistically higher in patients (n=12, 37.5%) compared to controls (n=0, 0%) (P<0.0001). The level of anti-MOG in Healthy Control (HC) was higher compared to patients with negative anti-MOG (P<0.0001) and was lower than patients with positive anti-MOG (P<0.0001). Conclusion: Our study showed that nearly one-third of seronegative NMOSD patients were positive for MOG-Ab. Further studies are needed to assess the characteristics and outcome of these patients. © 2021 The Authors. All Rights Reserved.
Other Related Docs
9. Frequency of Comorbidities in Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis and Related Disorders (2021)
15. Diagnosis and Classification of Optic Neuritis, The Lancet Neurology (2022)
18. Whole Spinal Transverse Myelitis in Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis and Related Disorders (2024)
20. Frequency of Diencephalic Syndrome in Nmosd, Acta Neurologica Belgica (2022)
42. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
43. Mri Signs of Cns Demyelinating Diseases, Multiple Sclerosis and Related Disorders (2021)
49. Vitamin D Level in Iranian Patients With Neuromyelitis Optica, Journal of Isfahan Medical School (2021)